Abstract
Rosacea is one of the most commonly occurring dermatoses treated by dermatologists. There are multiple therapeutic options available for the treatment of papulopustular rosacea. Rosacea is an inflammatory condition, classically presenting with flushing and/or blushing along with erythema, edema, telangiectasia, papules, pustules, and nodules of the face. Minocycline, a member of the tetracycline family, has demonstrated benefit in the treatment of inflammatory lesions in patients with rosacea. This manuscript highlights the use of a new sustained-release low-dose minocycline 45 mg tablet, with or without azelaic acid, for the treatment of papulopustular rosacea.
Publication types
-
Comparative Study
-
Meta-Analysis
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Cutaneous
-
Administration, Oral
-
Delayed-Action Preparations
-
Dermatologic Agents / administration & dosage
-
Dermatologic Agents / therapeutic use*
-
Dicarboxylic Acids / administration & dosage
-
Dicarboxylic Acids / therapeutic use*
-
Double-Blind Method
-
Drug Therapy, Combination
-
Female
-
Follow-Up Studies
-
Humans
-
Male
-
Minocycline / administration & dosage
-
Minocycline / therapeutic use*
-
Rosacea / drug therapy*
-
Rosacea / pathology
-
Treatment Outcome
Substances
-
Delayed-Action Preparations
-
Dermatologic Agents
-
Dicarboxylic Acids
-
azelaic acid
-
Minocycline